Clinical Trial Update: Phase IIa Dose-Expansion and Biomarker Study of OPB-111077 [Phase 2]

View source ↗

Summary

Phase IIa dose-expansion and biomarker study of OPB-111077 for nasopharyngeal carcinoma and refractory tumors, with current status unspecified.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• OPB-111077

Snippet

Sponsor: National University Hospital, Singapore | Conditions: NPC, Refractory Tumor | Phase 2 | Status: UNKNOWN